Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC-nabpac for Peritoneal Carcinomatosis
NCT03304210Phase 1Completed
- Sponsor
- Ghent University Hospital
- Start
- Sep 2017
- Primary completion
- May 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nab-paclitaxel in peritoneal carcinomatosis (PC) (5 arms), sponsored by Ghent University Hospital. Primary endpoint: Maximally Tolerated Dose at 14 weeks. Started Sep 2017; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT03304210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304210.